"Ozempic" may appear in Ukrainian pharmacies by the end of May, and the release of "Wegovy" is expected next year

Novo Nordisk is likely to hold an official presentation of the drug Ozempic in Ukraine as early as next week. According to available information, the event may take place on May 15, 2026, and the drug itself could appear in pharmacies before the end of the month. This was reported by the President of the Association of Dietitians of Ukraine, Professor, Head of the Department of Public Health and Nutrition at NUBiP of Ukraine, nutritionist, and gastroenterologist Oleh Shvets in a post on his Facebook page, according to UNN.

Details

"Sufficiently reliable information has emerged that Novo Nordisk will finally hold the official presentation of the drug Ozempic (officially registered in Ukraine back in 2022) in a week, on 15.05.2026. And that the drug will appear in pharmacies before the end of May. This is very good news, albeit quite overdue,"

It is also reported that the drug "Wegovy," which is also used for weight loss, will appear in pharmacies.

"Ozempic's 'sibling,' which has official indications for the treatment of obesity under the name Wegovy and has also been registered for two years, will appear in our pharmacies next year,"

In addition, the professor reported on the possible registration of a Ukrainian generic semaglutide, adding that this could happen in the coming months.

"And even better news concerns the registration of a Ukrainian generic semaglutide. There is a good chance that this will happen in the coming months. Then both the cost and availability of the drugs will not depend on the strategies of the global pharmacological game. We are waiting and preparing for changes in our practice and for better opportunities for patient treatment,"

Additionally

Ukrainian generic semaglutide is an analogue of well-known drugs (such as Ozempic or Wegovy), which is planned for release and registration in Ukraine in 2026 after the original manufacturer loses patent protection.

As a reminder

In the United States, the number of lawsuits is rapidly growing against manufacturers of semaglutide-based drugs, including Ozempic. Patients accuse pharmaceutical companies of failing to properly warn about the risks of serious side effects.